Article

The progesterone receptor regulates the expression of TRPV4 channel.

Laboratory of Molecular Physiology and Channelopathies, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Edifici PRBB, Parc de Recerca Biomèdica de Barcelona, Room 343, C/Dr. Aiguader 88, Barcelona, 08003, Spain.
Pflügers Archiv - European Journal of Physiology (Impact Factor: 4.87). 09/2009; 459(1):105-13. DOI: 10.1007/s00424-009-0706-7
Source: PubMed

ABSTRACT The transient receptor potential cationic channel TRPV4 contributes to different aspects of cell physiology via the generation of a Ca2+ signal and/or depolarization of the membrane potential. TRPV4 channel integrates distinct physical and chemical stimuli, including osmotic and mechanical stress, heat, acidic pH, endogenous ligands, and synthetic agonists such as 4alpha-phorbol 12,13-didecanoate (4alphaPDD). Although several regulatory sites controlling TRPV4 channel activity have been identified, very little is known about the regulation of TRPV4 expression, a situation common to other TRP channels. Here we show that TRPV4 expression is under the control of progesterone in both human airways and mammary gland epithelial cells, as well as in vascular smooth muscle cells. Exposure of human airways epithelial CFT1-LCFSN and mammary gland epithelial T47D cells to progesterone decreased TRPV4 mRNA and protein expression. Consequently, 4alphaPDD-induced cationic currents and Ca2+ signals were also diminished in progesterone-treated cells. The effect of progesterone was reverted by the progesterone receptor (PR) antagonist RU-486 or following transfection with small interference RNA (siRNA) against both PRA and PRB isoforms. Interestingly, TRPV4 expression and activity were increased in T47D mammary gland epithelial cells when PR was silenced with siRNA. Transcriptional regulation of -1.3 kB TRPV4 promoter-luciferase plasmids was also evaluated in vascular smooth muscle cells. TRPV4 promoter activity was reduced by coexpression with PR and further reduced in the presence of PG. Together, our data report the regulation of TRPV4 expression by progesterone, a process that requires a functional PR.

1 Bookmark
 · 
93 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Voltage-gated ether à-go-go-1 (EAG1) potassium channels are potential tumour markers and cancer therapeutic targets, and are up-regulated by oestrogens and human papilloma virus (HPV) oncogenes. However, the role of EAG1 in normal tissues is poorly understood, and its expression in pregnancy is unknown. We wondered whether EAG1 channels are expressed in cervical cells from pregnant patients and if progesterone regulates EAG1. The association with HPV was also investigated. EAG1 protein expression was studied by immunocytochemistry in liquid-based cervical cytologies, 93 samples were obtained from pregnant patients at different trimesters, and 15 samples were obtained from non-pregnant women (controls). The presence of HPV was studied by PCR with direct sequencing and nested-multiplex PCR. HeLa cervical cancer cells were transfected with human progesterone receptor-B (PR-B) and treated with progesterone. EAG1 mRNA expression in these cultures was studied by real-time PCR. EAG1 protein was detected in 100% of the pregnancy samples and in 26% of the controls. We found 18 pregnant patients infected with HPV and detected 14 types of HPV. There was no association between the percentage of cells expressing EAG1 and either the presence or type of HPV. Progesterone induced EAG1 mRNA and protein expression in cells transfected with human PR-B. No regulation of EAG1 by progesterone was observed in non-transfected cells. We show for the first time the expression of an ion channel during human pregnancy at different trimesters and EAG1 regulation by progesterone in human cells. These data raise a new research field for EAG1 channels in human tissues.
    Reproduction 09/2013; · 3.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ca(2+) influx through Ca(2+) permeable ion channels is a key trigger and regulator of a diverse set of cellular events, such as neurotransmitter release and muscle contraction. Ca(2+) influx is also a regulator of processes relevant to cancer, including cellular proliferation and migration. This review focuses on calcium influx in breast cancer cells as well as the potential for pharmacological modulators of specific Ca(2+) influx channels to represent future agents for breast cancer therapy. Altered expression of specific calcium permeable ion channels is present in some breast cancers. In some cases, such changes can be related to breast cancer subtype and even prognosis. In vitro and in vivo models have now helped identify specific Ca(2+) channels that play important roles in the proliferation and invasiveness of breast cancer cells. However, some aspects of our understanding of Ca(2+) influx in breast cancer still require further study. These include identifying the mechanisms responsible for altered expression and the most effective therapeutic strategy to target breast cancer cells through specific Ca(2+) channels. The role of Ca(2+) influx in processes beyond breast cancer cell proliferation and migration should become the focus of studies in the next decade.
    British Journal of Pharmacology 02/2014; 171(4):945-60. · 5.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is the most frequently occurring cancer in women and has the highest rate of mortality. Ion channels such as the transient receptor potential (TRP) channels could play a critical role in the development and progression of cancer. Although these channels are frequently and abundantly expressed in many tumors, their expression, activity, and roles in the context of breast cancer remain poorly understood. This review summarizes our current knowledge regarding TRP channels expressed in human breast tissue, primary human breast epithelial cells, and cell lines, the functional role of TRP channels during breast cancer cell growth and migration, as well as their relationship with clinical and pathological features.
    Trends in Molecular Medicine 12/2012; · 9.57 Impact Factor

Full-text

View
24 Downloads
Available from
Jun 2, 2014